Supriya Lifescience Limited (“SLL”) was incorporated on March 26, 2008. SLL is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. Company’s focus is primarily on diverse therapeutic areas and niche products. In Fiscal 2021, the company’s products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.

Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company’s manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.

For year/ period ended ( in Cr.)

• Significant scale with a leadership position across key & niche products
• Backward integrated business model;
• Advanced manufacturing and research and development capabilities;
• Consistent financial performance due to de-risked business model;
• The experienced senior management team and qualified operational personnel.

• Funding capital expenditure requirements of the company
• Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the company and
• General corporate purposes

SLL has niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. They have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India. At the upper band of Issue is priced at 15.21x with annualized EPS of 18.02x as at the end of H1FY22. P/BV is 5.99 at book value of 45.76 as at the end of H1FY22. The sector P/E is 23.03x which indicates that the Issue is attractively priced. Hence, investors can consider with a long-term perspective.